Micreos BV, of the Hague, Netherlands, secured €12 million (US$13 million) in additional equity for the global development of its antibacterial lysin technology, Staphefekt, in new products. Micreos intends to use the secured funds, which run until 2017, for the global development of Staphefekt as a pharmaceutical product. Micreos develops targeted antibacterial technology as a sustainable alternative to antibiotics, the company said, and its Gladskin is the world's first lysine-based product registered for human use. It specifically targets Staphylococcus aureus, including methicillin-resistant strains on intact skin.

Proteostasis Therapeutics Inc., of Cambridge, Mass., closed its IPO of 6.25 million shares of common stock at $8 each. Gross proceeds from the offering are $50 million. Leerink Partners and RBC Capital Markets acted as joint book-running managers. Baird and H.C. Wainwright & Co. served as co-managers. (See BioWorld Today, Feb. 12, 2016.)